Our corporate headquarters are located at:
Xeris Biopharma
180 North LaSalle Street
Suite 1600
Chicago, IL 60601
Xeris Biopharma was founded in 2005.
Xeris Biopharma is incorporated in Delaware.
Xeris Biopharma commenced its initial public offering (IPO) in June 2018.
Xeris Biopharma's fiscal year ends December 31st.
Xeris Biopharma’s common stock is listed on the NASDAQ Global Select Market under the symbol “XERS”.
The transfer agent and registrar for the common stock of Xeris Biopharma is
Computershare Trust Company, N.A.
Regular Delivery:
Computershare
P.O. Box 43006
Providence, RI 02940-3006
By Overnight Delivery:
Computershare
150 Royal Street, Suite 101
Canton, MA 02021
For questions about your stock please contact our transfer agent, Computershare Trust Company, N.A.
Online: Computershare Investor Services, https://www-us.computershare.com/investor/Contact
Phone: (800) 736-3001 (US, Canada, Puerto Rico); (781) 575-3100 (non-US)
Email: web.queries@computershare.com
To change the address on your shareholder account, you must send both your old and new addresses to our transfer agent:
Computershare
150 Royal Street, Suite 101
Canton, MA 02021
Xeris Biopharma does not have a direct stock purchase plan.
The auditor for Xeris Biopharma is KPMG LLC, located in Chicago Illinois.
Legal counsel for Xeris Biopharma is Goodwin Procter LLP located in Boston, Massachusetts.
You can view our press releases and financial reports at any time.
Xeris Biopharma's SEC Filings can be found on www.sec.gov or in the Financials section of this site.